In the subgroup of cMDD subjects, only 2 of the 28 analytes differed significantly between antidepressant users vs non-users (growth-regulated alpha protein (GROa) and IGFBP5); and 2 of the 28 analytes differed significantly between cases with and without comorbid anxiety (interleukin-1 receptor antagonist and FABPA; data not shown). The gene discussed is IGFBP5; the disease is Anxiety.